Evidence map›Paper›PMID 38081436›Full record

ArticleBrain, behavior, and immunity2024

The biology of hope: Inflammatory and neuroendocrine profiles in ovarian cancer patients.

Susan K Lutgendorf, Rachel M Telles, Brendan Whitney, Premal H Thaker, George M Slavich, Michael J Goodheart, Frank J Penedo, Alyssa E Noble, Steven W Cole, Anil K Sood and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain, behavior, and immunity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Susan K LutgendorfDepartment of Psychological & Brain Sciences, University of Iowa, Iowa City, IA, United States; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, United States; Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA, United States. Electronic address: susan-lutgendorf@uiowa.edu.
Rachel M TellesDepartment of Psychological & Brain Sciences, University of Iowa, Iowa City, IA, United States.
Brendan WhitneyDepartment of Psychological & Brain Sciences, University of Iowa, Iowa City, IA, United States.
Premal H ThakerDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO, United States.
George M SlavichCousins Center for Psychoneuroimmunology, University of California, Los Angeles, CA, United States; Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, United States.
Michael J GoodheartHolden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, United States; Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA, United States.
Frank J PenedoDepartments of Psychology and Medicine and Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States.
Alyssa E NobleDepartment of Psychological & Brain Sciences, University of Iowa, Iowa City, IA, United States.
Steven W ColeCousins Center for Psychoneuroimmunology, University of California, Los Angeles, CA, United States; Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, United States; Division of Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA, United States.
Anil K SoodDepartments of Gynecologic Oncology, Cancer Biology and Center for RNA Interference and Noncoding RNA, University of Texas M.D. Anderson Cancer Center, Houston, TX, United States.
Benjamin W CornShaare Zedek Medical Center, Jerusalem, Israel; Hebrew University Faculty of Medicine, Jerusalem, Israel.
University of Iowa · USUniversity of California, Los Angeles · USHebrew University of Jerusalem · ILThe University of Texas MD Anderson Cancer Center · USUniversity of Miami · USWashington University in St. Louis · US

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Douglas Robert Spitz · 2000 to 2026
$70.0M
Harnessing the power of exosomes for non-coding RNA deliveryR35CA209904 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SOOD, ANIL K · 2017 to 2023
$5.0M
Ovarian Cancer: Mechanisms of Neuroendocrine RegulationR01CA109298 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SOOD, ANIL K · 2005 to 2017
$4.5M
Behavioral Influences on Ovarian Cancer Progression: Role of ChemoresistanceR01CA193249 · NCI · UNIVERSITY OF IOWA · PI LUTGENDORF, SUSAN K · 2016 to 2020
$3.2M
Living Well: A Web-based Intervention to Improve Quality of Life in Rural and Urban Ovarian Cancer SurvivorsR01CA246540 · NCI · UNIVERSITY OF IOWA · PI LUTGENDORF, SUSAN K · 2020 to 2024
$3.0M
Biobehavioral Influences and the Ovarian Tumor MicroenvironmentR01CA140933 · NCI · UNIVERSITY OF IOWA · PI LUTGENDORF, SUSAN K · 2009 to 2013
$2.8M
Mechanisms of Health and Disease at the Behavioral-Biomedical InterfaceT32GM108540 · NIGMS · UNIVERSITY OF IOWA · PI LUTGENDORF, SUSAN K, VOSS, MICHELLE WEBB · 2014 to 2023
$1.7M
NCI NIH HHS P30 CA086862NCI NIH HHS R01 CA109298NCI NIH HHS R01 CA140933NCI NIH HHS R01 CA193249NCI NIH HHS R01 CA246540NCI NIH HHS R35 CA209904NIGMS NIH HHS T32 GM108540
6 · The paper itself

Abstract

introductionAlthough the concept of hope is highly relevant for cancer patients, little is known about its association with cancer-relevant biomarkers. Here we examined how hope was related to diurnal cortisol and interleukin-6 (IL-6), a pro-inflammatory cytokine previously associated with tumor biology and survival in ovarian cancer. Secondly, we examined whether hope and hopelessness are distinctly associated with these biomarkers.

methodParticipants were 292 high-grade ovarian cancer patients who completed surveys and provided saliva samples 4x/daily for 3 days pre-surgery to assess diurnal cortisol. Blood (pre-surgery) and ascites were assessed for IL-6. Hope and hopelessness were assessed using standardized survey items from established scales (Center for Epidemiological Studies Depression Scale; Profile of Mood States, Functional Assessment of Cancer Therapy). Two hopeless items were z-scored and combined into a composite for analysis. Regression models related these variables to nocturnal cortisol, cortisol slope, plasma and ascites IL-6, adjusting for cancer stage, BMI, age, and depression.

resultsGreater hope was significantly related to a steeper cortisol slope, β = -0.193, p = 0.046, and lower night cortisol, β = -0.227, p = 0.018, plasma IL-6, β = -0.142, p = 0.033, and ascites IL-6, β = -0.290, p = 0.002. Secondary analyses including both hope and hopelessness showed similar patterns, with distinct relationships of hope with significantly lower nocturnal cortisol β = -0.233,p = 0.017 and ascites IL-6, β = -0.282,p = 0.003, and between hopelessness and a flatter cortisol slope, β = 0.211, p = 0.031.

conclusionsThese data suggest a biological signature of hope associated with less inflammation and more normalized diurnal cortisol in ovarian cancer. These findings have potential clinical utility but need replication with more diverse samples and validated assessments of hope.

Indexed as

HydrocortisoneOvarian NeoplasmsAscitesBiologyBiomarkersCircadian RhythmDepressionFemaleHumansInterleukin-6SalivaBiomarkersHydrocortisoneInterleukin-6Diurnal cortisolHopeHopelessnessInflammationInterleukin-6Ovarian cancerPositive psychology

Identifiers

PMID38081436
PMCPMC11219272
OpenAlexW4389510103

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.